Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSNGet Free Report) have received a consensus rating of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $4.25.

Several brokerages have recently issued reports on MRSN. Wedbush reiterated an “outperform” rating and issued a $4.00 price objective on shares of Mersana Therapeutics in a research note on Monday, March 3rd. William Blair began coverage on Mersana Therapeutics in a research note on Thursday, February 6th. They issued an “outperform” rating on the stock.

Read Our Latest Research Report on Mersana Therapeutics

Institutional Trading of Mersana Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Los Angeles Capital Management LLC raised its stake in Mersana Therapeutics by 8.1% in the third quarter. Los Angeles Capital Management LLC now owns 189,660 shares of the company’s stock valued at $358,000 after buying an additional 14,240 shares in the last quarter. US Bancorp DE acquired a new stake in Mersana Therapeutics in the third quarter valued at $31,000. Dynamic Technology Lab Private Ltd acquired a new stake in Mersana Therapeutics in the third quarter valued at $34,000. Wells Fargo & Company MN raised its stake in Mersana Therapeutics by 40.3% in the fourth quarter. Wells Fargo & Company MN now owns 67,483 shares of the company’s stock valued at $97,000 after buying an additional 19,368 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in Mersana Therapeutics by 28.7% in the fourth quarter. SG Americas Securities LLC now owns 112,291 shares of the company’s stock valued at $161,000 after buying an additional 25,058 shares in the last quarter. 93.92% of the stock is currently owned by institutional investors and hedge funds.

Mersana Therapeutics Trading Up 3.0 %

MRSN opened at $0.48 on Thursday. Mersana Therapeutics has a 52 week low of $0.44 and a 52 week high of $5.11. The business has a fifty day simple moving average of $0.62 and a 200-day simple moving average of $1.49. The firm has a market cap of $59.70 million, a P/E ratio of -0.79 and a beta of 1.67. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 13.35.

Mersana Therapeutics (NASDAQ:MRSNGet Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. The business had revenue of $16.36 million for the quarter, compared to analysts’ expectations of $7.71 million. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. On average, equities analysts expect that Mersana Therapeutics will post -0.62 earnings per share for the current year.

About Mersana Therapeutics

(Get Free Report

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.

See Also

Analyst Recommendations for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.